title: Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial.
abstract: To confirm superiority on glycaemic control by switching from sitagliptin to liraglutide 1.8 mg/d versus continued sitagliptin.
  
  
  
  A randomized, multicentre, double-blind, double-dummy, active-controlled trial across 86 office- or hospital-based sites in North America, Europe and Asia. Subjects with type 2 diabetes who had inadequate glycaemic control (glycated haemoglobin [HbA1c] 7.5-9.5% on sitagliptin (100 mg/d) and metformin (≥1500 mg daily) for ≥90 days were randomized to either switch to liraglutide (n = 203) or continue sitagliptin (n = 204), both with metformin. The primary endpoint was change in HbA1c from baseline to week 26. Change in body weight was a confirmatory secondary endpoint.
  
  
  
  Greater reduction in mean HbA1c was achieved with liraglutide than with continued sitagliptin [-1.14% vs. -0.54%; estimated mean treatment difference (ETD): -0.61% (95% CI -0.82 to -0.40; p < 0.0001)], confirming superiority of switching to liraglutide. Body weight was reduced more with liraglutide [-3.31 kg vs. -1.64 kg; ETD: -1.67 kg (95% CI -2.34 to -0.99; p < 0.0001)]. Nausea was more common with liraglutide [44 subjects (21.8%)] than with continued sitagliptin [16 (7.8%)]. Three subjects (1.5%) taking sitagliptin reported a confirmed hypoglycaemic episode.
  
  
  
  Subjects insufficiently controlled with sitagliptin who switch to liraglutide can obtain clinically relevant reductions in glycaemia and body weight, without compromising safety. A switch from sitagliptin to liraglutide provides an option for improved management of type 2 diabetes while still allowing patients to remain on dual therapy.
authors.affiliation: AMCR Institute, Escondido, California, USA.
authors.forename: T S
authors.initials: TS
authors.lastname: Bailey
authors.affiliation: First Department of Medicine, University of Szeged, Szeged, Hungary.
authors.forename: R
authors.initials: R
authors.lastname: Takács
authors.affiliation: Department of Clinical Endocrinology and Nutrition, IBIMA, Hospital Virgen de la Victoria, CIBERobn, Instituto de Salud Carlos III, University of Málaga, Málaga, Spain.
authors.forename: F J
authors.initials: FJ
authors.lastname: Tinahones
authors.affiliation: Kumudini Devi Diabetes Research Center, Ramdevrao Hospital, Hyderabad, Telangana, India.
authors.forename: P V
authors.initials: PV
authors.lastname: Rao
authors.affiliation: Department of Endocrinology and Metabolism, McGill University Health Centre, Montreal, Canada.
authors.forename: G M
authors.initials: GM
authors.lastname: Tsoukas
authors.affiliation: Global Development, Medical and Science, GLP-1 and Obesity, Novo Nordisk A/S, Søborg, Denmark.
authors.forename: A B
authors.initials: AB
authors.lastname: Thomsen
authors.affiliation: Global Development, Medical and Science, GLP-1 and Obesity, Novo Nordisk A/S, Søborg, Denmark.
authors.forename: M S
authors.initials: MS
authors.lastname: Kaltoft
authors.affiliation: Atherosclerosis and Metabolism Unit, Soroka UMC, Ben-Gurion University FOHS, Be'er Sheva, Israel.
authors.forename: M
authors.initials: M
authors.lastname: Maislos
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001208:Asia; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D004311:Double-Blind Method; D057915:Drug Substitution; D004359:Drug Therapy, Combination; D005060:Europe; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000069450:Liraglutide / Q000627:therapeutic use*; D008297:Male; D008687:Metformin / Q000627:therapeutic use; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009656:North America; D000068900:Sitagliptin Phosphate / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000069450:Liraglutide; D008687:Metformin; D000068900:Sitagliptin Phosphate; C517652:hemoglobin A1c protein, human
keywords: GLP-1 receptor agonist; liraglutide; sitagliptin; type 2 diabetes